SAN DIEGO, CA--(Marketwire - February 28, 2013) -
Naviscan, the manufacturer of the Positron Emission Mammography (PEM) Scanner
and the Stereo Navigator® Biopsy Accessory is attending the Miami Breast Cancer Conference on March 7 - 10, 2013 in Miami Beach, Florida. Naviscan in conjunction with Nuclear Medicine Distributors (NMD) will have both products on display on the conference floor.
The Naviscan PEM scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early breast cancer diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.
The Stereo Navigator is the first commercially available breast PET-guided biopsy accessory, enabling clinicians to guide compatible interventional devices towards abnormalities visible on PET.
"It is with great satisfaction that we will collaborate with Naviscan during the 30th Annual Miami Breast Cancer Conference," said Mauro Ferreira, General Manager, NMD. "This will be an opportunity for Latin America medical professionals to have direct access to the system and get to know its unique characteristics and benefits."
"We consider the Miami Breast Conference to be a major clinical exhibit with over 1,000 attendees from the U.S. and Latin America," states Paul J. Mirabella, CEO, Naviscan, Inc. "It is an honor to attend with our Latin America distributor, NMD, particularly when the diffusion of our technology is accelerating throughout the region."
Headquartered in Panama City, Panama, NMD has operations in four countries. NMD, focused on Molecular Imaging, Proton Therapy and Intra Operative Radiotherapy, is a part of a holding company with more than $130 million (US) in assets, two FDG plants, approximately 800 direct employees and operations in seven countries.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.